{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:30:13Z","timestamp":1792870213699,"version":"4.5.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anai.2026.06.035","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T15:15:54Z","timestamp":1782573354000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biomarkers for chronic obstructive pulmonary disease (COPD) with type-2 inflammation"],"prefix":"10.1016","author":[{"given":"Chetna","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Suri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-7520","authenticated-orcid":false,"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2026.06.035_bib0001","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease. GOLD report. Accessed March 19, 2025. Available at: https:\/\/goldcopd.org\/2025-gold-report\/"},{"issue":"10342","key":"10.1016\/j.anai.2026.06.035_bib0002","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting Type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0005","unstructured":"European Respiratory Society. Type 2 airway inflammation in COPD. Accessed December 15, 2025. Available at: https:\/\/publications.ersnet.org\/content"},{"issue":"11","key":"10.1016\/j.anai.2026.06.035_bib0006","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.jaip.2022.04.034","article-title":"Cigarette smoking and asthma","volume":"10","author":"Thomson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00561-2019","article-title":"Bronchodilator reversibility in asthma and COPD: findings from three large population studies","volume":"54","author":"Janson","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.06.035_bib0008","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/COPD.S385733","article-title":"Bronchodilator responsiveness defined by the 2005 and 2021 ERS\/ATS criteria in patients with asthma as well as chronic obstructive pulmonary disease","volume":"17","author":"Li","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.anai.2026.06.035_bib0009","series-title":"Global Strategy for Asthma Management and Prevention (2025 Update)","year":"2025"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0010","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2026.06.035_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302318","article-title":"High blood eosinophils predict the risk of COPD exacerbation: A systematic review and meta-analysis","volume":"19","author":"Chen","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","article-title":"Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis","volume":"21","author":"Harries","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2026.06.035_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106880","article-title":"A systematic review of blood eosinophils and continued treatment with inhaled corticosteroids in patients with COPD","volume":"198","author":"Dalin","year":"2022","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: A Global Initiative for Chronic Obstructive Lung Disease science committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5753524","article-title":"Understanding the cellular sources of the fractional exhaled nitric oxide (FeNO) and its role as a biomarker of Type 2 inflammation in asthma","volume":"2022","author":"Escamilla-Gil","year":"2022","journal-title":"Biomed Res Int"},{"issue":"37","key":"10.1016\/j.anai.2026.06.035_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000044307","article-title":"Predictors of fractional exhaled nitric oxide response to inhaled corticosteroid therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"104","author":"Lee","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"47","key":"10.1016\/j.anai.2026.06.035_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011922","article-title":"Treatment of chronic obstructive pulmonary disease in patients with different fractional exhaled nitric oxide levels","volume":"97","author":"Wu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"suppl 1","key":"10.1016\/j.anai.2026.06.035_bib0018","doi-asserted-by":"crossref","DOI":"10.3399\/bjgp24X737745","article-title":"Role of FeNO in predicting the responsiveness of inhaled corticosteroids in COPD: a systematic review","volume":"74","author":"Ramesh","year":"2024","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.anai.2026.06.035_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107682","article-title":"Correlation of fractional exhaled nitric oxide (FeNO) and clinical outcomes in patients with chronic obstructive pulmonary disease: a prospective cohort study","volume":"229","author":"Keeratichananont","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108134","article-title":"Short term exacerbation risk and exhaled nitric oxide in COPD","volume":"243","author":"Romero-Linares","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107831","article-title":"Association between acute tobacco exposure and fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease: national health and Nutrition Examination Survey (NHANES) 2007-2012","volume":"234","author":"Hou","year":"2024","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0022","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.anai.2026.06.035_bib0023","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of Type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.anai.2026.06.035_bib0024","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2026.06.035_bib0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/imr.12557","article-title":"Innate and adaptive type 2 immunity in lung allergic inflammation","volume":"278","author":"Kubo","year":"2017","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0027","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2019","article-title":"Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue","volume":"55","author":"Jogdand","year":"2020","journal-title":"Eur Respir J"},{"issue":"9998","key":"10.1016\/j.anai.2026.06.035_bib0029","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","article-title":"Targeting the interleukin pathway in the treatment of asthma","volume":"386","author":"Chung","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2026.06.035_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.851940","article-title":"Interleukins 4 and 13 in asthma: key pathophysiologic cytokines and druggable molecular targets","volume":"13","author":"Pelaia","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.anai.2026.06.035_bib0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0032","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/all.14741","article-title":"Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Fricker","year":"2021","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI124606","article-title":"Epithelial cell-derived cytokines: more than just signaling the alarm","volume":"129","author":"Roan","year":"2019","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0033","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaci.2022.07.003","article-title":"TSLP, IL-33, and IL-25: not just for allergy and helminth infection","volume":"150","author":"Stanbery","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.03.032","article-title":"TSLP drives acute TH2-cell differentiation in lungs","volume":"146","author":"Lai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2022","article-title":"Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE\/EGFR signalling complex","volume":"62","author":"Strickson","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.anai.2026.06.035_bib0037","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0038","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0039","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"337","key":"10.1016\/j.anai.2026.06.035_bib0040","doi-asserted-by":"crossref","first-page":"337ra65","DOI":"10.1126\/scitranslmed.aaf1938","article-title":"Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2 cytokine-driven inflammation and fibrosis","volume":"8","author":"Vannella","year":"2016","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.anai.2026.06.035_bib0041","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJMra1411863","article-title":"The asthma\u2013COPD overlap syndrome","volume":"373","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0042","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaip.2025.10.033","article-title":"Revisiting Type 2 inflammation and airway hyper-responsiveness in COPD","volume":"14","author":"Suter","year":"2026","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0043","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.alit.2025.07.003","article-title":"From mucus plugging to airway dilatation in chronic airway diseases: a perspective on the contribution of the airway microbiome and inflammation","volume":"75","author":"Tanabe","year":"2026","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2016.03.050","article-title":"Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients","volume":"139","author":"Wawrzyniak","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.02.038","article-title":"Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients","volume":"141","author":"Sugita","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.06.035_bib0046","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2147\/COPD.S147144","article-title":"Characteristics and potential role of M2 macrophages in COPD","volume":"12","author":"He","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0047","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaci.2005.06.031","article-title":"Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis","volume":"116","author":"Gomes","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"10.1016\/j.anai.2026.06.035_bib0048","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0049","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/rr83","article-title":"Small airway inflammation in asthma","volume":"2","author":"Tulic","year":"2001","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0050","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.202301-0149OC","article-title":"Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease","volume":"208","author":"Cabrera L\u00f3pez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0051","article-title":"Different airway inflammatory phenotypes correlate with specific fungal and bacterial microbiota in asthma and chronic obstructive pulmonary disease","volume":"2022","author":"Yang","year":"2022","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.10.046","article-title":"Eosinophilic airway inflammation in asthmatic patients is associated with an altered airway microbiome","volume":"140","author":"Sverrild","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0053","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.201710-2112OC","article-title":"Staphylococcus aureus induces a mucosal Type 2 immune response via epithelial cell-derived cytokines","volume":"198","author":"Lan","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0054","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaci.2005.12.1360","article-title":"Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization","volume":"117","author":"Mandron","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0055","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01592-2019","article-title":"Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge","volume":"55","author":"Bachert","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0056","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0058","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0059","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00838-2020","article-title":"High eosinophil counts predict decline in FEV1: results from the CanCOLD study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.anai.2026.06.035_bib0064","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0075","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00427-2018","article-title":"The reproducibility of COPD blood eosinophil counts","volume":"52","author":"Southworth","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0076","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.chest.2019.04.012","article-title":"Stability of the blood eosinophilic phenotype in stable and exacerbated COPD","volume":"156","author":"Schumann","year":"2019","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0077","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.202105-1162LE","article-title":"Blood eosinophil counts in chronic obstructive pulmonary disease: adding within-day variability to the equation","volume":"205","author":"Van Rossem","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0080","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.anai.2026.06.035_bib0083","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1164\/rccm.202109-2093ST","article-title":"Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society Clinical Practice guideline","volume":"204","author":"Khatri","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0091","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.2147\/COPD.S434040","article-title":"The relationship of fractional exhaled nitric oxide in patients with AECOPD","volume":"18","author":"Xu","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"23","key":"10.1016\/j.anai.2026.06.035_bib0093","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010857","article-title":"Diagnostic value of fractional exhaled nitric oxide for asthma-chronic obstructive pulmonary disease overlap syndrome","volume":"97","author":"Guo","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.anai.2026.06.035_bib0094","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2147\/COPD.S257965","article-title":"Predictive value of exhaled nitric oxide and blood eosinophil count in the assessment of airway eosinophilia in COPD","volume":"15","author":"Antus","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.anai.2026.06.035_bib0095","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/jcm11102791","article-title":"The combined value of Type2 inflammatory markers in chronic obstructive pulmonary disease","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0096","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0104","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70057","article-title":"IgE in allergic diseases","volume":"334","author":"Greene","year":"2025","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-021-01847-0","article-title":"IgE is associated with exacerbations and lung function decline in COPD","volume":"23","author":"Lommatzsch","year":"2022","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.anai.2022.06.028","article-title":"Plasma immunoglobulin E and risk of exacerbation and mortality in chronic obstructive pulmonary disease: a contemporary population-based cohort","volume":"129","author":"\u00c7olak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0111","doi-asserted-by":"crossref","DOI":"10.1080\/15412555.2025.2579360","article-title":"IgE guided use of ICS in patients with stable COPD: A real-world observational study","volume":"22","author":"Zhou","year":"2025","journal-title":"COPD"},{"key":"10.1016\/j.anai.2026.06.035_bib0112","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/COPD.S140748","article-title":"Effect of allergic phenotype on treatment response to inhaled bronchodilators with or without inhaled corticosteroids in patients with COPD","volume":"12","author":"Cheng","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.anai.2026.06.035_bib0113","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejim.2025.04.001","article-title":"The impact of sensitization patterns on COPD severity and exacerbations: insights from a case-control and longitudinal study","volume":"136","author":"Karakioulaki","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108605","article-title":"Allergic sensitization in asthma and COPD in the NOVELTY study","volume":"251","author":"Janson","year":"2026","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0115","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.chest.2020.04.069","article-title":"Clinical phenotypes of atopy and asthma in COPD: A meta-analysis of SPIROMICS and COPDGene","volume":"158","author":"Putcha","year":"2020","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0116","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1164\/rccm.202103-0583OC","article-title":"Home dust allergen exposure is associated with outcomes among sensitized individuals with chronic obstructive pulmonary disease","volume":"205","author":"Putcha","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0117","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-14-10","article-title":"Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP study","volume":"14","author":"Fattahi","year":"2013","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.anai.2026.06.035_bib0118","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(25)00044-X","article-title":"Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Christenson","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0119","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5114\/ada.2022.113804","article-title":"Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap","volume":"39","author":"Ricciardi","year":"2022","journal-title":"Adv Dermatol Allergol Dermatol Alergol"},{"key":"10.1016\/j.anai.2026.06.035_bib0120","article-title":"Comparative effectiveness of omalizumab in asthma-COPD overlap vs asthma: a retrospective cohort study","volume":"13","author":"Sun","year":"2026","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0121","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chest.2016.09.035","article-title":"Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD","volume":"151","author":"Maltby","year":"2017","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.anai.2026.06.035_bib0122","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/02770903.2016.1178281","article-title":"Omalizumab treatment in asthma-COPD overlap syndrome","volume":"53","author":"Tat","year":"2016","journal-title":"J Asthma"},{"key":"10.1016\/j.anai.2026.06.035_bib0057","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/biomedicines10061412","article-title":"Airway eosinophilia on bronchoalveolar lavage and the risk of exacerbations in COPD","volume":"10","author":"Ho","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.anai.2026.06.035_bib0060","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/thoraxjnl-2019-214457","article-title":"Association between COPD exacerbations and lung function decline during maintenance therapy","volume":"75","author":"Kerkhof","year":"2020","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.anai.2026.06.035_bib0061","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0062","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","article-title":"Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0063","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.035_bib0066","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01219-2018","article-title":"Inhaled corticosteroids in COPD: friend or foe?","volume":"52","author":"Agusti","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0067","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","article-title":"Blood eosinophils as a marker of response to inhaled corticosteroids in COPD","volume":"47","author":"Barnes","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0068","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/jcm8070962","article-title":"Reassessing the role of eosinophils as a biomarker in chronic obstructive pulmonary disease","volume":"8","author":"Tin\u00e8","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0069","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12016-015-8525-4","article-title":"The eosinophil in infection","volume":"50","author":"Ravin","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12016-015-8507-6","article-title":"The eosinophil in health and disease: from bench to bedside and back","volume":"50","author":"Liao","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0071","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12016-015-8526-3","article-title":"The role and immunobiology of eosinophils in the respiratory system: a comprehensive review","volume":"50","author":"Eng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0072","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/00365513.2011.602422","article-title":"Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations","volume":"71","author":"Sennels","year":"2011","journal-title":"Scand J Clin Lab Invest"},{"issue":"7470","key":"10.1016\/j.anai.2026.06.035_bib0073","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nature12526","article-title":"Type 2 innate lymphoid cells control eosinophil homeostasis","volume":"502","author":"Nussbaum","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0074","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/07420528.2023.2231079","article-title":"The effect of shift work on different hematological parameters among healthcare workers","volume":"40","author":"Sooriyaarachchi","year":"2023","journal-title":"Chronobiol Int"},{"key":"10.1016\/j.anai.2026.06.035_bib0078","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"suppl 63","key":"10.1016\/j.anai.2026.06.035_bib0079","first-page":"OA260","article-title":"Analysis of Impact: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?","volume":"54","author":"Bafadhel","year":"2019","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.12.019","article-title":"Associations between individual characteristics and blood eosinophil counts in adults with asthma or COPD","volume":"8","author":"Caspard","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0082","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1513\/AnnalsATS.202010-1249OC","article-title":"A comprehensive analysis of the stability of blood eosinophil levels","volume":"18","author":"Chipps","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.anai.2026.06.035_bib0084","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2147\/COPD.S165780","article-title":"Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/thoraxjnl-2020-214644","article-title":"Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease","volume":"77","author":"Annangi","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2026.06.035_bib0086","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.niox.2025.06.003","article-title":"Appearances can be deceiving: differences in FeNO values among COPD and severe asthmatic patients stratified according to peripheral eosinophilic count","volume":"158","author":"Candia","year":"2025","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.anai.2026.06.035_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106612","article-title":"Fractional exhaled nitric oxide in acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis with meta-regressions","volume":"145","author":"Ambrosino","year":"2026","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0088","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000046615","article-title":"Correlation of fractional exhaled nitric oxide levels with inflammation and lung function in patients with chronic obstructive pulmonary disease at different stages: a retrospective study","volume":"105","author":"Sheng","year":"2026","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0089","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17476348.2024.2433537","article-title":"Measuring exhaled nitric oxide in COPD: from theoretical consideration to practical views","volume":"18","author":"H\u00f6gman","year":"2024","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/resp.14439","article-title":"Variability of fractional exhaled nitric oxide is associated with the risk and aetiology of COPD exacerbations","volume":"28","author":"Schumann","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.anai.2026.06.035_bib0092","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2147\/COPD.S273422","article-title":"The value of inflammatory biomarkers in differentiating asthma-COPD overlap from COPD","volume":"15","author":"Li","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0097","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1378\/chest.128.4.2465","article-title":"Time-dependent effect of nitrate-rich meals on exhaled nitric oxide in healthy subjects","volume":"128","author":"Vints","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.anai.2026.06.035_bib0098","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2022.133411","article-title":"A food composition database for assessing nitrate intake from plant-based foods","volume":"394","author":"Zhong","year":"2022","journal-title":"Food Chem"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0099","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/antiox9030241","article-title":"Nitrates\/nitrites in food-risk for nitrosative stress and benefits","volume":"9","author":"Karwowska","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"9","key":"10.1016\/j.anai.2026.06.035_bib0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1164\/rccm.200310-1473OC","article-title":"Effect of caffeine ingestion on exhaled nitric oxide measurements in patients with asthma","volume":"169","author":"Taylor","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2026.06.035_bib0101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/thorax.57.4.361","article-title":"Caffeine decreases exhaled nitric oxide","volume":"57","author":"Bruce","year":"2002","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/15412555.2019.1704231","article-title":"Fractional exhaled nitric oxide is associated with the severity of stable COPD","volume":"17","author":"Liu","year":"2020","journal-title":"COPD"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0103","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1172\/JCI119473","article-title":"Mechanisms of nitric oxide-related antimicrobial activity. Perspectives series: host\/pathogen interactions","volume":"99","author":"Fang","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2026.06.035_bib0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejphar.2015.05.070","article-title":"The high-affinity immunoglobulin E receptor as pharmacological target","volume":"778","author":"Blank","year":"2016","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2567.1998.00418.x","article-title":"High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans\u2019 cells in allergen-induced late-phase cutaneous reactions in atopic subjects","volume":"93","author":"Ying","year":"1998","journal-title":"Immunology"},{"issue":"5","key":"10.1016\/j.anai.2026.06.035_bib0107","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0091-6749(97)70033-2","article-title":"Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: relationship to total serum IgE concentrations","volume":"99","author":"Sihra","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2026.06.035_bib0108","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood.V93.8.2543","article-title":"Functional expression of the high affinity receptor for IgE (FcepsilonRI) in human platelets and its\u2019 intracellular expression in human megakaryocytes","volume":"93","author":"Hasegawa","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.anai.2026.06.035_bib0124","article-title":"MCP-4 and Eotaxin-3 are novel biomarkers for chronic obstructive pulmonary disease","volume":"2023","author":"Fang","year":"2023","journal-title":"Can Respir J"},{"key":"10.1016\/j.anai.2026.06.035_bib0125","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/COPD.S304488","article-title":"PARC\/CCL18 is associated with inflammation, emphysema severity and application of inhaled corticosteroids in hospitalized COPD patients","volume":"16","author":"Duan","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"10.1016\/j.anai.2026.06.035_bib0126","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/rccm.201008-1220OC","article-title":"Serum PARC\/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease","volume":"183","author":"Sin","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0127","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12931-018-0818-8","article-title":"Serum periostin does not reflect type 2-driven inflammation in COPD","volume":"19","author":"Carpaij","year":"2018","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.anai.2026.06.035_bib0129","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021322","article-title":"The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease","volume":"350","author":"Celli","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2026.06.035_bib0130","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD Assessment Test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.anai.2026.06.035_bib0131","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE)","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2026.06.035_bib0132","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.anai.2026.06.035_bib0133","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2026.06.035_bib0134","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to Benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and Terranova studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2026.06.035_bib0135","series-title":"Update on the RESOLUTE Phase III Trial for Fasenra (Benralizumab) in Chronic Obstructive Pulmonary Disease. Astra Zeneca PLC News Release","author":"Astra","year":"2025"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0136","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with Benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib0137","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"The Lancet Respiratory Medicine"},{"issue":"11","key":"10.1016\/j.anai.2026.06.035_bib0138","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"issue":"1","key":"10.1016\/j.anai.2026.06.035_bib139","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626003030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:53:25Z","timestamp":1788983605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626003030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":139,"alternative-id":["S1081120626003030"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.035","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers for chronic obstructive pulmonary disease (COPD) with type-2 inflammation","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}